XML 164 R101.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenues and other income - Additional Information (Details) $ in Thousands |  |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 04, 2023 USD ($) | Nov. 07, 2023 USD ($) | Jul. 07, 2023 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2024 EUR (€) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2021 EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  | € (7,191,000) |  | € 36,207,000 | € 4,776,000 |  |  |
Current contract liabilities |  |  |  |  | 18,100,000 |  | 18,100,000 |  |  |  |
Current contract assets |  |  |  |  | 0 |  | 2,062,000 |  |  |  |
Capital increases |  |  |  |  | 0 |  | 60,154,000 | 0 |  |  |
Refund liabilities |  |  |  |  | 35,613,000 |  | 0 |  |  |  |
Other income |  |  |  |  | 4,419,000 |  | 6,150,000 | 4,776,000 |  |  |
Revenues |  |  |  |  | € (11,609,000) |  | 30,058,000 | 0 |  |  |
Research tax credit utilization period |  |  |  |  | 3 years | 3 years |  |  |  |  |
Trade receivables |  |  |  |  | € 2,977,000 |  | 905,000 |  |  |  |
Research tax credit |  |  |  |  | 3,300,000 |  | 3,900,000 |  |  |  |
Subsidies |  |  |  |  | 89,000 |  | 229,000 | 135,000 |  |  |
Net loss for the period |  |  |  |  | 68,132,000 |  | 39,700,000 |  |  |  |
Services |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | (17,534,000) |  | 29,750,000 | 0 |  |  |
Other sales |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 5,924,000 |  | 308,000 | 0 |  |  |
Janssen |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment license fee | $ |  |  | $ 30,000 |  |  |  |  |  |  |  |
Collaboration agreement, success-based payment | $ |  |  | 1,800,000 |  |  |  |  |  |  |  |
Proceeds receivable due to milestone completion | $ |  |  |  |  |  |  |  |  |  | $ 20,000 |
Capital increases | $ |  |  | 30,000 |  |  |  |  |  |  |  |
Revenues |  |  |  |  | (1,600,000) |  | (1,600,000) |  |  |  |
Janssen | Services |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | (23,400,000) |  | 29,600,000 |  |  |  |
Net loss for the period |  |  |  |  | 19,300,000 |  |  |  |  |  |
Janssen | Research and Development |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | (4,000,000) |  |  |  |  |  |
Janssen | Technology transfer |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Refund liabilities |  |  |  |  | 35,600,000 |  |  |  |  |  |
Revenues |  |  |  |  | (1,800,000) |  | 100,000 |  |  |  |
Janssen | Other sales |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | € 5,900,000 |  | 300,000 |  |  |  |
Janssen | Tranche one |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Capital increases | $ |  |  |  |  |  | $ 5,000 |  |  |  |  |
Janssen | Tranche two |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Capital increases | $ | $ 4,800 | $ 20,200 |  |  |  | $ 25,000 |  |  |  |  |
Janssen | Top of Range |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Potential development and commercial milestones payments | $ |  |  | 650,000 |  |  |  |  |  |  |  |
Collaboration agreement, compensation per indication | $ |  |  | 220,000 |  |  |  |  |  |  |  |
Janssen | Top of Range | Nanobiotix Corp. |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, compensation per indication | $ |  |  | $ 220,000 |  |  |  |  |  |  |  |
LianBio, NBTXR3 |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Current contract liabilities |  |  |  |  |  |  |  |  |  |  | € 16,500,000
Minimum threshold to provide additional know-how to third party under collaboration agreement |  |  |  |  | 80.00% | 80.00% |  |  |  |  |
Collaboration agreement, amount collected |  |  |  |  | € 1,100,000 |  |  |  |  |  |
Upfront payment received | $ |  |  |  | $ 20,000 |  |  |  |  | $ 20,000 |  |
Trade receivables |  |  |  |  |  |  | 300,000 |  |  |  |
Supply Services |  |  |  |  | 1,000,000 |  | 2,000,000 | € 500,000 |  |  |
LianBio, NBTXR3 | Maximum |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Potential development and commercial milestones payments | $ |  |  |  | $ 205,000 |  |  |  |  |  |  |
LianBio, NBTXR3 and Cetuximab |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, amount collected |  |  |  |  |  |  | 334,300 |  |  |  |
Other income |  |  |  |  | 237,000 |  | € 1,600,000 |  |  |  |
Global Trial Clinical Agreement |  |  |  |  |  |  |  |  |  |  |
Disclosure of disaggregation of revenue from contracts with customers [line items] |  |  |  |  |  |  |  |  |  |  |
Other income |  |  |  |  | € 778,000 |  |  |  |  |  |

X
- Definition The amount of current contract assets. [Refer: Contract assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentContractAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of current trade receivables. [Refer: Trade receivables] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 68 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentTradeReceivables
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of operating income that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 26 -IssueDate 2024-01-01 -Paragraph 35 -Subparagraph b -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_OtherIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 37 -IssueDate 2024-01-01 -Section Example 4 Refunds policy -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 37 -IssueDate 2024-01-01 -Paragraph 87 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_87&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RefundsProvision
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition A component of equity representing the entity’s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 78 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RetainedEarningsProfitLossForReportingPeriod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 28 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 23 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 32 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 33 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard -URIDate 2024-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard -URIDate 2024-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2024-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2024-03-27 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 82 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard -URIDate 2024-03-27 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard -URIDate 2024-03-27 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of income recognised in relation to government grants. [Refer: Government grants] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 20 -IssueDate 2024-01-01 -Paragraph 39 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RevenueFromGovernmentGrants
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Collected + References No definition available. + Details
Name: | nbx_CollaborationAgreementCollected
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Potential Milestones Payments To Be Received + References No definition available. + Details
Name: | nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication + References No definition available. + Details
Name: | nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Success-Based Payment + References No definition available. + Details
Name: | nbx_CollaborationAgreementSuccessBasedPayment
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment License Fee + References No definition available. + Details
Name: | nbx_CollaborationAgreementUpfrontPaymentLicenseFee
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment Received + References No definition available. + Details
Name: | nbx_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement + References No definition available. + Details
Name: | nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement
Namespace Prefix: | nbx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds Due From Collaboration Agreements, Milestone Payment + References No definition available. + Details
Name: | nbx_ProceedsDueFromCollaborationAgreementsMilestonePayment
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research Tax Credit + References No definition available. + Details
Name: | nbx_ResearchTaxCredit
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research Tax Credit Utilization Period + References No definition available. + Details
Name: | nbx_ResearchTaxCreditUtilizationPeriod
Namespace Prefix: | nbx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Supply Services + References No definition available. + Details
Name: | nbx_SupplyServices
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nbx_TechnologyTransferMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_TrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbx_NanobiotixCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3AndCetuximabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_GlobalTrialClinicalAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |